Comparative effectiveness of plasma-derived and recombinant FVIII concentrates in the on-demand and prophylactic treatment of patients with haemophilia A.
Pollmann
H
H
Richter
H
H
Siegmund
B
B
D005169:Factor VIII / Q000627:therapeutic use*; D006395:Hemarthrosis / Q000517:prevention & control*; D006467:Hemophilia A / Q000517:prevention & control*; D006801:Humans; D010949:Plasma; D055502:Secondary Prevention; D016896:Treatment Outcome
C078147:F8 protein, human; D005169:Factor VIII